Zydus Lifesciences has informed that it enclosed a copy of press release dated April 25, 2022 titled 'Zydus announces publication of ‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat in ‘American Journal of Nephrology’.
The above information is a part of company’s filings submitted to BSE.